MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on May 9, 2008; DOI: 10.1124/mol.107.044651

0026-895X/08/7402-423-431$20.00
Mol Pharmacol 74:423-431, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.044651v1
74/2/423    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Stepanov, A.
Right arrow Articles by Nitiss, J. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stepanov, A.
Right arrow Articles by Nitiss, J. L.

Enhancing Drug Accumulation in Saccharomyces cerevisiae by Repression of Pleiotropic Drug Resistance Genes with Chimeric Transcription Repressors

Alexander Stepanov, Karin C. Nitiss, Geoffrey Neale, and John L. Nitiss

St. Jude Children's Research Hospital, Molecular Pharmacology, Memphis, Tennessee (A.S., K.C.N., J.L.N.); and St. Jude Children's Research Hospital, Hartwell Center Bioinformatics & Biotechnology, Memphis, Tennessee (G.N.)

Yeast is a powerful model system for studying the action of small-molecule therapeutics. An important limitation has been low efficacy of many small molecules in yeast due to limited intracellular accumulation. We used the DNA binding domain of the pleiotropic drug resistance regulator pleiotropic drug resistance 1 (Pdr1) fused in-frame to transcription repressors to repress Pdr1-regulated genes. Expression of these chimeric regulators conferred dominant enhancement of sensitivity to a different class of compounds and led to greatly diminished levels of Pdr1p-regulated transcripts, including the yeast p-glycoprotein homolog Pdr5. Enhanced sensitivity was seen for a wide range of small molecules. Biochemical measurements demonstrated enhanced accumulation of rhodamine in yeast cells expressing the chimeric repressors. These repressors of Pdr1p-regulated transcripts can be introduced into large collections of strains such as the Saccharomyces cerevisiae deletion set and enhance the utility of yeast for studying drug action and for mechanism-based drug discovery.

Received December 23, 2007; accepted May 9, 2008

Address correspondence to: Dr. John L. Nitiss, St. Jude Children's Research Hospital, Molecular Pharmacology Department, 332 N. Lauderdale, Memphis, TN 38105. E-mail: john.nitiss{at}stjude.org






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics